Geno J. Germano Buys 3,605 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL) Stock

Precision BioSciences, Inc. (NASDAQ:DTIL) Director Geno J. Germano acquired 3,605 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was bought at an average price of $4.49 per share, with a total value of $16,186.45. Following the acquisition, the director now directly owns 7,807 shares of the company’s stock, valued at $35,053.43. The trade was a 85.79 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Precision BioSciences Stock Up 1.3 %

Shares of Precision BioSciences stock opened at $4.75 on Friday. Precision BioSciences, Inc. has a 1 year low of $3.61 and a 1 year high of $19.43. The business has a 50-day moving average of $6.44 and a two-hundred day moving average of $8.44. The company has a market capitalization of $36.44 million, a P/E ratio of 79.18 and a beta of 1.41. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22.

Institutional Investors Weigh In On Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Janus Henderson Group PLC grew its holdings in Precision BioSciences, Inc. (NASDAQ:DTIL) by 10.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 702,069 shares of the company’s stock after acquiring an additional 68,943 shares during the quarter. Janus Henderson Group PLC owned 9.15% of Precision BioSciences worth $6,322,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.